Enhertu (fam-trastuzumab deruxtecan-nxki)

Enhertu produced a 55.6% objective response rate in HER2-positive non-small cell lung cancer patients in a phase 1 trial.

Angus Liu Mar 25, 2020 8:23am

Dec 11, 2019 8:00am